|Articles|September 2, 2014

"Evidence" Trail Elusive - Video

Nancy Dreyer, PhD, MPH, FISPe, discusses the importance of non-interventional studies.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

What Operation TrialBlazer Actually Requires of Sponsors and Research Teams

ByAmber Hill, PhD,Andy Studna, Senior Editor

August 17th 2026

© photon_photo - © photon_photo - stock.adobe.com

One Clinical: Working Together to Advance Trial Collaboration

August 17th 2026

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

ByAndy Studna, Senior Editor

August 17th 2026

Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV

ByRaviv Pryluk, PhD,Andy Studna, Senior Editor

August 14th 2026

© Andrii Yalanskyi - © Andrii Yalanskyi - stock.adobe.com

Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad

ByAndy Studna, Senior Editor

August 14th 2026

Trending on Applied Clinical Trials Online

The CRA of the Future: From Monitoring Activity to Strategic Site Partnership

Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad

ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps